跳至主要内容
临床试验/NL-OMON52409
NL-OMON52409招募中不适用

Concentration-guided dose reduction versus standard dosing in tocilizumab-treated rheumatoid arthritis patients: a randomised, international, multicenter, non-inferiority trial (TODORA) - Use of tocilizumab drug levels to optimize treatment of RA (TODORA)

Jan van Breemen Instituut0 个研究点目标入组 88 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
88

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Rheumatoid arthritis according to the ACR 1897 or 2010 criteria;
  • - Current use of subcutaneous tocilizumab 162 mg weekly, for at least the last
  • - The treating rheumatologist is convinced of the benefit of tocilizumab
  • continuation;
  • - No changes in the treatment with glucocorticoids and DMARDs such as
  • methotrexate in the past 3 months;
  • - Written informed consent.

排除标准

  • A scheduled surgery in the next 12 months or other pre-planned reasons for
  • treatment discontinuation.

研究者

发起方
Jan van Breemen Instituut

相似试验